Intrexon gets $115M in new Merck partnership
Germantown-based biotechnology company Intrexon Corp. will receive an upfront payment of $115 million in a new collaboration and licensing agreement with Merck Serono, the biopharmaceutical business of German drug giant Merck.
Together, the companies will develop and commercialize cancer therapies that modulate the human body’s own immune system’s ability to fight tumors.
The research will focus on generically engineered T-cells with synthetic receptors that attack cancer cells. Research will…